Related Experiment Video

Updated: Aug 11, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Juvenile idiopathic arthritis: current and future treatment options

Giorgia Martini1, Francesco Zulian

  • 1Department of Pediatric Rheumatology, University of Padua, Italy.

Expert Opinion on Pharmacotherapy
|March 1, 2006
PubMed

Insights

Juvenile idiopathic arthritis (JIA) management has improved with targeted therapies. New anti-tumor necrosis factor (anti-TNF) agents show promise in treating this common childhood rheumatic disease.

Area of Science:

  • Rheumatology
  • Pediatrics
  • Immunology

Background:

  • Juvenile idiopathic arthritis (JIA) is the most prevalent rheumatic condition in children.
  • Significant advancements in JIA management have led to reduced disease morbidity.
  • Improved drug efficacy and combination therapies have transformed patient outcomes.

Purpose of the Study:

  • To review current medical management strategies for juvenile idiopathic arthritis.
  • To discuss emerging therapeutic agents targeting inflammatory pathways in JIA.
  • To highlight the role of cytokine-targeting therapies, particularly anti-TNF agents.

Main Methods:

  • Review of current literature on juvenile idiopathic arthritis management.
  • Analysis of clinical trial data for novel therapeutic agents.
  • Discussion of mechanisms of action for targeted immunotherapies.

Main Results:

  • Anti-tumor necrosis factor (anti-TNF) agents demonstrate significant efficacy in JIA.
  • Etanercept is currently the only licensed anti-TNF agent for JIA.
  • Ongoing Phase III trials for infliximab and adalimumab indicate potential new treatment options.

Conclusions:

  • Current JIA management benefits from advanced pharmacotherapies.
  • Targeted therapies, especially anti-TNF agents, are revolutionizing JIA treatment.
  • Future therapeutic strategies will likely involve novel agents and refined treatment protocols.

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...